NMC Health Plc Independent review investigators (1388A)
17 Gennaio 2020 - 8:00AM
UK Regulatory
TIDMNMC
RNS Number : 1388A
NMC Health Plc
17 January 2020
17 January 2020
NMC Health Independent Committee Retains Former FBI Director
Louis Freeh to Conduct Independent Investigation
NMC Has Previously Called Assertions Made by Short Sellers
'Unfounded, Baseless and Misleading'.
The Independent Review Committee ("the Committee") formed by NMC
Health plc (LSE: NMC), the leading private healthcare operator in
the Gulf Cooperation Council (GCC) with international services
across 19 countries, announced that it has retained Louis Freeh,
former Federal Judge and FBI Director, and his firm Freeh Group
International Solutions, LLC ("FGIS"), to examine and compile a
report regarding allegations raised in the 17 December 2019 report
from short seller Muddy Waters and by certain other third
parties.
"The Committee chose Freeh Group to provide a completely
independent, unbiased, comprehensive and transparent report that
will address all of these allegations," said Jonathan Bomford,
Chairman of the Independent Review Committee.
FGIS is a global risk management firm serving in the areas of
business integrity and compliance, safety and security, and
investigations and due diligence. FGIS was founded by Louis Freeh,
former director of the U.S. Federal Bureau of Investigation (FBI)
and former federal judge. In addition to Judge Freeh, the
management team of FGIS includes former senior law enforcement
officials, legal consultants, accountants, and security and
compliance experts.
As previously announced, the Committee is undertaking an
independent review of all allegations, focusing initially on
confirmation of the Group's cash balances as at 15 December 2019.
The Committee intends to publish findings of the review into all
primary allegations made, particularly all those of a financial
nature, in advance of the release of the Company's 2019 financial
results.
In the meantime, NMC remains focused on our business, strategy
and wider stakeholders and on continuing to generate long-term
returns and value for our shareholders.
Contacts
NMC
Asjad Yahya, Investor Relations +971 (0)56 219 0975
About NMC Health
NMC is one of the leading private healthcare operators in the
Gulf Cooperation Council ("GCC") with an international network of
multi-specialty inpatient and outpatient clinics and hospitals,
specialized maternity and fertility clinics, and long-term care
homes hospitals across nineteen countries. NMC also ranks as one of
the top two in-vitro fertilisation operators globally. The NMC
Health group is recognised as a leading provider of long-term
medical care in the UAE through its subsidiary ProVita. Pursing a
selective international expansion programme since 2016, NMC has
total capacity of 2,207 licensed beds across its network. Moreover,
the recent formation of a joint venture with GOSI/Hassana
Investment Company provides a solid platform for continued growth
in the GCC region's largest healthcare market. The NMC Health group
treated over 7.5 million patients in 2018. The NMC Health group is
also a leading UAE supplier of products and consumables coming from
healthcare related products. NMC reported revenues of US$2.1
billion for the year ended 31 December 2018.
In April 2012, NMC was listed on the Premium Segment of the
London Stock Exchange. NMC is a constituent of the FTSE 100
Index.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCGLGDBBDBDGGR
(END) Dow Jones Newswires
January 17, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Nmc Health (LSE:NMC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Nmc Health (LSE:NMC)
Storico
Da Apr 2023 a Apr 2024